Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesLymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Mariette X et al. – The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar as that expected for such patients with severe inflammatory diseases. However, some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
Methods- National prospective registry (RATIO) from 2004 to 2006
- All cases of lymphoma in French patients receiving anti-TNF therapy, whatever the indication collected
- Case-control analysis including 2 controls treated with anti-TNF per case and an incidence study of lymphoma with French population used as reference
- Collected 38 cases of lymphoma, 31 non-Hodgkin’s lymphoma (NHL) (26 B-cell and 5 T-cell), 5 Hodgkin’s lymphoma (HL) and 2 Hodgkin’s-like lymphoma
- Epstein-Barr virus (EBV) detected in 2 of 2 Hodgkin’s-like lymphoma, 3 of 5 HL and 1 NHL
- Patients receiving adalimumab or infliximab had higher risk than those treated with etanercept: SIR = 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8)
- Exposure to adalimumab or infliximab versus etanercept independent risk factor for lymphoma in case-control study: odds ratio=4.7 (1.3–17.7) and 4.1 (1.4–12.5), respectively
- Sex and age- adjusted incidence rate of lymphoma was 42.1 per 100,000 patient-y
- Standardized incidence ratio (SIR) 2.4 (95% confidence interval [CI] 1.7–3.2)
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations
British Journal of Haematology, 11/20/09
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression
Molecular Cancer, 11/20/09
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines
Molecular Cancer, 11/20/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Toxicity of Bisphosphonates
Journal of Palliative Medicine, 11/20/09
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration
World Journal of Surgical Oncology, 11/20/09
Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia
Journal of Oncology, 11/20/09
Sponsor
Article Search
Sponsor
Sponsor